{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:26:41Z","timestamp":1788935201570,"version":"build-2803163510"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The COVID-19 pandemic affected millions of people and has become a dominant etiology of olfactory dysfunction (OD). No interventions with definitive clinical utility exist. Gabapentin represents a potential therapy for COVID-19\u2013induced OD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy of oral gabapentin on olfactory function and olfaction-related quality of life in patients with COVID-19\u2013induced OD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This pilot double-blinded, placebo-controlled randomized clinical trial (RCT) was conducted at Washington University School of Medicine in St Louis from January 7, 2022, to February 3, 2023. Adults with at least 3 months of OD after COVID-19 infection were eligible for inclusion. Participants with a history of other causes of OD or contraindications to gabapentin were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Patients were randomized 1:1 to oral gabapentin or placebo. All patients underwent titration to a maximum tolerable dose, which was maintained during an 8-week fixed-dose (FD) phase then tapered off. Participants were monitored for 4 weeks following cessation of study medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Outcomes were assessed following the 8-week FD phase and 4 weeks after taper completion. The primary outcome measure was the response rate determined by subjective improvement in OD on the Clinical Global Impression of Improvement (CGI-I) after the FD phase. Other subjective and objective measures of olfactory function were also assessed as secondary outcome measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-eight participants were enrolled (34 randomized to each arm), a total of 44 participants completed the FD period and 20 (45.4%) reported response to treatment with at least slight improvement in olfaction from baseline. Of those randomized, 51 (75%) were women and 56 were White (82%) with a mean (SD) age of 43 (13.5) years. Baseline demographic features including age, sex, and race and ethnicity were not significantly different between the groups. Of the 18 participants in the gabapentin group, 8 (44%) were responders and of the 26 participants in the placebo group, 12 (46%) reported response to treatment (percent difference, 1.7%; 95% CI, \u221231.6% to 28.2%). Mixed-model analysis of all secondary outcome measures demonstrated no clinically meaningful or statistically significant difference between the gabapentin and placebo groups throughout the trial. There were no serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this randomized clinical trial, gabapentin was not associated with statistically significant or clinically meaningful benefit over placebo and likely is not an efficacious therapy for COVID-19\u2013induced OD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05184192\">NCT05184192<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2023.2958","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T15:02:08Z","timestamp":1695308528000},"page":"1111","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of Gabapentin For Post\u2013COVID-19 Olfactory Dysfunction"],"prefix":"10.1001","volume":"149","author":[{"given":"Ashna","family":"Mahadev","sequence":"first","affiliation":[{"name":"Clinical Outcomes Research Office, Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri"},{"name":"University of Missouri-Kansas City School of Medicine, Kansas City, Missouri"},{"name":"Family Care Health Centers, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Hentati","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Research Office, Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brevin","family":"Miller","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Research Office, Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri"},{"name":"University of Missouri-Kansas City School of Medicine, Kansas City, Missouri"},{"name":"Family Care Health Centers, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bao","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Research Office, Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri"},{"name":"University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Perrin","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Research Office, Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorina","family":"Kallogjeri","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Research Office, Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay F.","family":"Piccirillo","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Research Office, Department of Otolaryngology\u2013Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"ooi230061r2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00405-020-05965-1","article-title":"Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.","volume":"277","author":"Lechien","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"ooi230061r3","first-page":"66","article-title":"The clinical course of smell and taste loss in COVID-19 hospitalized patients.","volume":"24","author":"Printza","year":"2020","journal-title":"Hippokratia"},{"issue":"20","key":"ooi230061r4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1001\/jama.2020.6771","article-title":"Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection.","volume":"323","author":"Spinato","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"ooi230061r5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1017\/S0022215121002279","article-title":"Impact of olfactory dysfunction on quality of life in coronavirus disease 2019 patients: a systematic review.","volume":"135","author":"Saniasiaya","year":"2021","journal-title":"J Laryngol Otol"},{"issue":"9","key":"ooi230061r6","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/lary.v132.9","article-title":"Depression symptoms and olfactory-related quality of life.","volume":"132","author":"Liu","year":"2022","journal-title":"Laryngoscope"},{"issue":"15","key":"ooi230061r7","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1021\/acschemneuro.0c00406","article-title":"Anosmia in COVID-19: a bumpy road to establishing a cellular mechanism.","volume":"11","author":"Bilinska","year":"2020","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"ooi230061r8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/jcm10050966","article-title":"Smell and taste loss recovery time in COVID-19 patients and disease severity.","volume":"10","author":"Printza","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"ooi230061r9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/foods11070967","article-title":"Emerging pattern of post-COVID-19 parosmia and its effect on food perception.","volume":"11","author":"Parker","year":"2022","journal-title":"Foods"},{"issue":"4","key":"ooi230061r10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/lary.v124.4","article-title":"Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study.","volume":"124","author":"Damm","year":"2014","journal-title":"Laryngoscope"},{"issue":"2","key":"ooi230061r11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaoto.2022.4112","article-title":"Efficacy of combined visual-olfactory training with patient-preferred scents as treatment for patients with COVID-19 resultant olfactory loss: a randomized clinical trial.","volume":"149","author":"Khan","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ooi230061r12","article-title":"Gabapentin improves parosmia after COVID-19 infection.","author":"Garcia","journal-title":"Int Forum Allergy Rhinol"},{"issue":"14","key":"ooi230061r13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1920827118","article-title":"Presynaptic a2d subunits are key organizers of glutamatergic synapses.","volume":"118","author":"Sch\u00f6pf","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ooi230061r14","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.4317\/medoral.16942","article-title":"Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial.","volume":"16","author":"L\u00f3pez-D\u2019alessandro","year":"2011","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"2 Pt 1","key":"ooi230061r15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1288\/00005537-198402000-00004","article-title":"University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic.","volume":"94","author":"Doty","year":"1984","journal-title":"Laryngoscope"},{"issue":"3","key":"ooi230061r16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamaoto.2021.3994","article-title":"Development and validation of a novel at-home smell assessment.","volume":"148","author":"Gupta","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"ooi230061r17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoto.2022.3299","article-title":"Development and psychometric validation of the olfactory dysfunction outcomes rating.","volume":"148","author":"Lee","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"ooi230061r18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/bs7030040","article-title":"Transdiagnostic clinical global impression scoring for routine clinical settings.","volume":"7","author":"Dunlop","year":"2017","journal-title":"Behav Sci (Basel)"},{"issue":"9","key":"ooi230061r19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/archneur.1997.00550210061014","article-title":"Olfactory dysfunction in patients with head trauma.","volume":"54","author":"Doty","year":"1997","journal-title":"Arch Neurol"},{"key":"ooi230061r20","article-title":"Validation of minimal clinically important difference (MCID) for University of Pennsylvania Smell Identification Test (UPSIT).","author":"Mahadev","journal-title":"American Journal of Rhinology & Allergy"},{"issue":"11","key":"ooi230061r21","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/lary.v132.11","article-title":"Intranasal corticosteroid treatment on recovery of long-term olfactory dysfunction due to COVID-19.","volume":"132","author":"Hosseinpoor","year":"2022","journal-title":"Laryngoscope"},{"key":"ooi230061r1","unstructured":"Centers for Disease Control and Prevention. CDC Covid Data tracker. Centers for Disease Control and Prevention. Retrieved December 28, 2022, from https:\/\/covid.cdc.gov\/covid-data-tracker\/#datatracker-home"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2809346\/jamaotolaryngology_mahadev_2023_oi_230061_1701290187.78677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T16:09:24Z","timestamp":1702570164000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2809346"}},"subtitle":["The GRACE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2023.2958","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}